This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
The use of dermal implants for improving acne scarring and facial rhytids has increased dramatically in the last ten years. The introduction of, and experience with, collagen dermal implants during that period has played a great role in this increased popularity. Dermal implants are now an adjunct to facial rejuvenation surgical procedures, and to the improvement of depressed cutaneous scars.
In March 1988, a new dermal implant (Fibrel) was approved by the US Food and Drug Administration for use in the elevation of depressed cutaneous scars. Fibrel is a gelatin matrix implant consisting of absorbable gelatin powder and aminocaproic acid, which is reconstituted with the patient's plasma before being injected intradermally beneath the scar. A total of 321 patients were evaluated after a skin sensitivity test; 2% had positive skin reactions. Eight hundred forty scars were treated with Fibrel implant material and followed up for approximately one year. About 6%
MITTELMAN H. Fibrel: A Dermal Implant Comparison With Collagen Implants. Arch Otolaryngol Head Neck Surg. 1988;114(12):1379. doi:10.1001/archotol.1988.01860240029017
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: